VERU Stock Analysis: Buy, Sell, or Hold?
VERU - Veru Inc.
$2.36
-0.21 (-8.01%)
▼
5d:
-18.23%
30d:
-27.76%
90d:
-1.05%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
27d
Get Alerted When VERU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called VERU this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: VERU is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: VERU is down 18.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: VERU is currently trading at $2.35, which is considered oversold relative to its 30-day fair value range of $2.76 to $3.18.
Technical Outlook: Technically, VERU is showing sideways momentum. Immediate support is located at $2.11, while resistance sits at $7.33. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+857.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VERU is showing sideways momentum. Immediate support is located at $2.11, while resistance sits at $7.33. Short-term momentum is weak, with the stock down 8.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (7th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $24.50 (+857.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.76 -
$3.18
Company Quality Score
61/100
(BUY)
Options IV Signal
7th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
82.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 7th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.0%)
- BULLISH: Trading 857.0% below Wall St target ($24.50)
- WARNING: Recommendation downgraded due to -18.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.76 -
$3.18
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.72
(30.5%)
Support & Resistance Levels
Support Level
$2.11
Resistance Level
$7.33
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.60
Wall Street Target
$24.50
(+857.0%)
Revenue Growth (YoY)
18.3%
Share & Embed Analysis
Last updated: July 14, 2026 3:43 PM ET
Data refreshes hourly during market hours. Next update: 4:43 PM
Data refreshes hourly during market hours. Next update: 4:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VERU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
